S. Grundy, Metabolic Complications of Obesity, Endocrine, vol.13, issue.2, pp.155-165, 2000.
DOI : 10.1385/ENDO:13:2:155

H. Xu, G. Barnes, Q. Yang, G. Tan, D. Yang et al., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, Journal of Clinical Investigation, vol.112, issue.12, pp.1821-1830, 2003.
DOI : 10.1172/JCI19451DS1

H. Tilg and A. Moschen, Inflammatory mechanisms in the regulation of insulin resistance, Mol Med, vol.14, pp.222-231, 2008.

C. Weyer, T. Funahashi, S. Tanaka, K. Hotta, Y. Matsuzawa et al., Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.5, pp.1930-1935, 2001.
DOI : 10.1210/jcem.86.5.7463
URL : https://academic.oup.com/jcem/article-pdf/86/5/1930/9163528/jcem1930.pdf

R. Carmena, J. Ascaso, and J. Real, Impact of obesity in primary hyperlipidemias, Nutr Metab Cardiovasc Dis, vol.11, pp.354-359, 2001.

R. Mechoulam, E. Fride, and D. Marzo, Endocannabinoids, European Journal of Pharmacology, vol.359, issue.1, pp.1-18, 1998.
DOI : 10.1016/S0014-2999(98)00649-9

T. Bisogno, A. Ligresti, D. Marzo, and V. , The endocannabinoid signalling system: Biochemical aspects, Pharmacology Biochemistry and Behavior, vol.81, issue.2, pp.224-238, 2005.
DOI : 10.1016/j.pbb.2005.01.027

A. Andre and M. Gonthier, The endocannabinoid system: Its roles in energy balance and potential as a target for obesity treatment, The International Journal of Biochemistry & Cell Biology, vol.42, issue.11, pp.1788-1801
DOI : 10.1016/j.biocel.2010.06.002
URL : https://hal.archives-ouvertes.fr/hal-01198341

P. Nagarkatti, R. Pandey, S. Rieder, V. Hegde, and M. Nagarkatti, Cannabinoids as novel anti-inflammatory drugs, Future Medicinal Chemistry, vol.115, issue.7, pp.1333-1349, 2009.
DOI : 10.1016/j.neulet.2004.06.060
URL : http://europepmc.org/articles/pmc2828614?pdf=render

S. Nissen, S. Nicholls, K. Wolski, J. Rodes-cabau, C. Cannon et al., Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease, JAMA, vol.299, issue.13, pp.1547-1560, 2008.
DOI : 10.1001/jama.299.13.1547

F. Pi-sunyer, L. Aronne, H. Heshmati, D. J. Rosenstock, and J. , Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients, JAMA, vol.295, issue.7, pp.761-775, 2006.
DOI : 10.1001/jama.295.7.761

J. Rosenstock, P. Hollander, C. S. Iranmanesh, and A. , SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes, Diabetes Care, vol.31, issue.11, pp.2169-2176, 2008.
DOI : 10.2337/dc08-0386

A. Scheen, N. Finer, P. Hollander, M. Jensen, V. Gaal et al., Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study, The Lancet, vol.368, issue.9548, pp.1660-1672, 2006.
DOI : 10.1016/S0140-6736(06)69571-8

V. Gaal, L. Rissanen, A. Scheen, A. Ziegler, O. Rossner et al., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, The Lancet, vol.365, issue.9468, pp.1389-1397, 2005.
DOI : 10.1016/S0140-6736(05)66374-X

J. Despres, R. Ross, G. Boka, N. Almeras, and I. Lemieux, Effect of Rimonabant on the High-Triglyceride/ Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.3, pp.416-423, 2009.
DOI : 10.1161/ATVBAHA.108.176362
URL : http://atvb.ahajournals.org/content/atvbaha/29/3/416.full.pdf

F. Dol-gleizes, R. Paumelle, V. Visentin, A. Mares, P. Desitter et al., Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor-Deficient Mice, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, issue.1, pp.12-18, 2009.
DOI : 10.1161/ATVBAHA.108.168757
URL : http://atvb.ahajournals.org/content/atvbaha/29/1/12.full.pdf

M. Gary-bobo, G. Elachouri, J. Gallas, P. Janiak, P. Marini et al., Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats, Hepatology, vol.330, issue.1, pp.122-129, 2007.
DOI : 10.1152/ajpregu.00545.2002
URL : http://onlinelibrary.wiley.com/doi/10.1002/hep.21641/pdf

K. Sugamura, S. Sugiyama, T. Nozaki, Y. Matsuzawa, Y. Izumiya et al., Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages, Circulation, vol.119, issue.1, pp.28-36, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.811992
URL : http://circ.ahajournals.org/content/circulationaha/119/1/28.full.pdf

A. Schafer, J. Pfrang, J. Neumuller, S. Fiedler, G. Ertl et al., The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats, British Journal of Pharmacology, vol.116, issue.5, pp.1047-1054, 2008.
DOI : 10.1161/01.CIR.103.13.1772

P. Trayhurn and I. Wood, Adipokines: inflammation and the pleiotropic role of white adipose tissue, British Journal of Nutrition, vol.14, issue.03, pp.347-355, 2004.
DOI : 10.1073/pnas.162349799
URL : https://www.cambridge.org/core/services/aop-cambridge-core/content/view/9680A60552772E2E6350FD0763A97506/S0007114504001795a.pdf/div-class-title-adipokines-inflammation-and-the-pleiotropic-role-of-white-adipose-tissue-div.pdf

I. Matias, M. Gonthier, P. Orlando, V. Martiadis, D. Petrocellis et al., Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and ??-Pancreatic Cells and in Obesity and Hyperglycemia, The Journal of Clinical Endocrinology & Metabolism, vol.91, issue.8, pp.3171-3180, 2006.
DOI : 10.1210/jc.2005-2679

M. Gonthier, L. Hoareau, F. Festy, I. Matias, M. Valenti et al., Identification of Endocannabinoids and Related Compounds in Human Fat Cells*, Obesity, vol.173, issue.4, pp.837-845, 2007.
DOI : 10.4049/jimmunol.174.6.3137
URL : http://onlinelibrary.wiley.com/doi/10.1038/oby.2007.581/pdf

R. Roche, L. Hoareau, S. Bes-houtmann, M. Gonthier, C. Laborde et al., Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes, Histochemistry and Cell Biology, vol.346, issue.1, pp.177-187, 2006.
DOI : 10.1172/JCI200319451

M. Gary-bobo, G. Elachouri, B. Scatton, L. Fur, G. Oury-donat et al., The Cannabinoid CB1 Receptor Antagonist Rimonabant (SR141716) Inhibits Cell Proliferation and Increases Markers of Adipocyte Maturation in Cultured Mouse 3T3 F442A Preadipocytes, Molecular Pharmacology, vol.69, issue.2, pp.471-478, 2006.
DOI : 10.1124/mol.105.015040

M. Bensaid, M. Gary-bobo, A. Esclangon, J. Maffrand, L. Fur et al., The Cannabinoid CB1 Receptor Antagonist SR141716 Increases Acrp30 mRNA Expression in Adipose Tissue of Obese fa/fa Rats and in Cultured Adipocyte Cells, Molecular Pharmacology, vol.63, issue.4, pp.908-914, 2003.
DOI : 10.1124/mol.63.4.908

Z. Yan, D. Liu, L. Zhang, C. Shen, Q. Ma et al., Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-??, Biochemical and Biophysical Research Communications, vol.354, issue.2, pp.427-433, 2007.
DOI : 10.1016/j.bbrc.2006.12.213

R. Motaghedi and T. Mcgraw, The CB1 endocannabinoid system modulates adipocyte insulin sensitivity. Obesity (Silver Spring), pp.1727-1734, 2008.
DOI : 10.1038/oby.2008.309
URL : http://onlinelibrary.wiley.com/doi/10.1038/oby.2008.309/pdf

D. Marzo, V. Goparaju, S. Wang, L. Liu, J. Batkai et al., Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature, vol.264, issue.6830, pp.822-825, 2001.
DOI : 10.1046/j.1432-1327.1999.00631.x

L. Hoareau, M. Buyse, F. Festy, P. Ravanan, M. Gonthier et al., Anti-inflammatory Effect of Palmitoylethanolamide on Human Adipocytes, Obesity, vol.406, issue.3, pp.431-438, 2009.
DOI : 10.1016/S0014-2999(00)00653-1
URL : https://hal.archives-ouvertes.fr/hal-01198351

K. Clement and S. Vignes, Adipokines, Inflammation, and Obesity, Rev Med Interne, vol.291, issue.Suppl. 1, pp.824-832, 2009.
DOI : 10.1152/ajpendo.00174.2006

L. Lay, S. Robichon, C. , L. Liepvre, X. Dagher et al., Regulation of ABCA1 expression and cholesterol efflux during adipose differentiation of 3T3-L1 cells, Journal of Lipid Research, vol.10, issue.8, pp.1499-1507, 2003.
DOI : 10.1021/bi010348m

P. Verghese, E. Arrese, and J. Soulages, Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes, Molecular and Cellular Biochemistry, vol.291, issue.1-2, pp.241-248, 2007.
DOI : 10.3181/00379727-167-41188

S. Zhao, Y. J. Li, J. Dong, S. Wu, and Z. , Effect of niacin on LXR?? and PPAR?? expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits, International Journal of Cardiology, vol.124, issue.2, pp.172-178, 2008.
DOI : 10.1016/j.ijcard.2006.12.032

K. Tsubakio-yamamoto, F. Matsuura, M. Koseki, H. Oku, J. Sandoval et al., Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages, Biochemical and Biophysical Research Communications, vol.375, issue.3, pp.390-394, 2008.
DOI : 10.1016/j.bbrc.2008.08.009

I. Matias, M. Gonthier, S. Petrosino, L. Docimo, R. Capasso et al., Role and regulation of acylethanolamides in energy balance: focus on adipocytes and ??-cells, British Journal of Pharmacology, vol.100, issue.5, pp.676-690, 2007.
DOI : 10.1152/ajpregu.00270.2006
URL : http://onlinelibrary.wiley.com/doi/10.1038/sj.bjp.0707424/pdf

F. Montecucco, I. Matias, S. Lenglet, S. Petrosino, F. Burger et al., Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis, Atherosclerosis, vol.205, issue.2, pp.433-441, 2009.
DOI : 10.1016/j.atherosclerosis.2008.12.040

G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali et al., Appetite suppression and weight loss after the cannabinoid antagonist SR 141716, Life Sciences, vol.63, issue.8, pp.113-117, 1998.
DOI : 10.1016/S0024-3205(98)00322-1

R. Trillou, C. Arnone, M. Delgorge, C. Gonalons, N. Keane et al., Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol.278, issue.2, pp.345-353, 2003.
DOI : 10.1073/pnas.96.10.5780

D. Osei-hyiaman, M. Depetrillo, P. Pacher, J. Liu, S. Radaeva et al., Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, Journal of Clinical Investigation, vol.115, issue.5, pp.1298-1305, 2005.
DOI : 10.1172/JCI200523057
URL : http://www.jci.org/articles/view/23057/files/pdf

D. Marzo and V. , CB1 receptor antagonism: biological basis for metabolic effects, Drug Discovery Today, vol.13, issue.23-24, pp.1026-1041, 2008.
DOI : 10.1016/j.drudis.2008.09.001

M. Ohman and D. Eitzman, Targeting MCP-1 to Reduce Vascular Complications of Obesity, Recent Patents on Cardiovascular Drug Discovery, vol.4, issue.3, pp.164-176, 2009.
DOI : 10.2174/157489009789152230

J. Hector, B. Schwarzloh, J. Goehring, T. Strate, U. Hess et al., TNF-?? Alters Visfatin and Adiponectin Levels in Human Fat, Hormone and Metabolic Research, vol.39, issue.4, pp.250-255, 2007.
DOI : 10.1055/s-2007-973075
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-2007-973075.pdf

A. Kakafika, D. Mikhailidis, A. Karagiannis, and V. Athyros, The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome, The Journal of Clinical Pharmacology, vol.45, issue.suppl, pp.642-652, 2007.
DOI : 10.1016/j.jacc.2005.02.080

A. Herling, S. Kilp, R. Elvert, G. Haschke, and W. Kramer, Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats, Endocrinology, vol.149, issue.5, pp.2557-2566, 2008.
DOI : 10.1210/en.2007-1515

J. Fain, B. Buehrer, D. Tichansky, and A. Madan, Regulation of adiponectin release and demonstration of adiponectin mRNA as well as release by the non-fat cells of human omental adipose tissue, International Journal of Obesity, vol.288, issue.3, pp.429-435, 2008.
DOI : 10.1152/ajpendo.00110.2003

T. Watanabe, N. Kubota, M. Ohsugi, T. Kubota, I. Takamoto et al., Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways, Journal of Biological Chemistry, vol.170, issue.3, pp.1803-1812, 2009.
DOI : 10.1046/j.1460-9568.2003.02504.x
URL : http://www.jbc.org/content/284/3/1803.full.pdf

S. Migrenne, A. Lacombe, A. Lefevre, M. Pruniaux, E. Guillot et al., Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol.296, issue.4, pp.929-935, 2009.
DOI : 10.1016/j.bbrc.2006.08.071
URL : http://ajpregu.physiology.org/content/ajpregu/296/4/R929.full.pdf

L. Bellocchio, C. Cervino, V. Vicennati, R. Pasquali, and U. Pagotto, Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes??? Bow, Journal of Neuroendocrinology, vol.19, issue.s1, pp.130-138, 2008.
DOI : 10.1016/50140-6736(06)69571-8
URL : http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2826.2008.01682.x/pdf

D. Marzo, V. Despres, and J. , CB1 antagonists for obesity???what lessons have we learned from rimonabant?, Nature Reviews Endocrinology, vol.14, issue.11, pp.633-638, 2009.
DOI : 10.1016/S1567-5688(08)70044-8

, Cite this article as: Murumalla et al.: Effect of the Cannabinoid Receptor- 1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation, Journal of Inflammation, vol.8, p.33, 2011.